Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Kharasch ED, Stubbert K.

Drug Metab Dispos. 2013 Dec;41(12):2166-74. doi: 10.1124/dmd.113.053991. Epub 2013 Sep 25.

PMID:
24067429
[PubMed - indexed for MEDLINE]
2.

Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS.

Anesthesiology. 2009 Mar;110(3):660-72. doi: 10.1097/ALN.0b013e3181986a9a.

PMID:
19225389
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D.

Anesthesiology. 2012 Feb;116(2):432-47. doi: 10.1097/ALN.0b013e3182423478.

PMID:
22273859
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS.

Drug Alcohol Depend. 2009 May 1;101(3):158-68. doi: 10.1016/j.drugalcdep.2008.12.009. Epub 2009 Feb 18.

PMID:
19232844
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C.

Clin Pharmacol Ther. 2008 Oct;84(4):506-12.

PMID:
19238656
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C.

Clin Pharmacol Ther. 2008 Oct;84(4):497-505.

PMID:
19238655
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Kharasch ED, Hoffer C, Whittington D, Sheffels P.

Clin Pharmacol Ther. 2004 Sep;76(3):250-69.

PMID:
15371986
[PubMed - indexed for MEDLINE]
8.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH.

Br J Pharmacol. 2010 Jul;160(5):1224-33. doi: 10.1111/j.1476-5381.2010.00759.x.

PMID:
20590614
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD.

J Pharm Sci. 2011 Jun;100(6):2508-15. doi: 10.1002/jps.22457. Epub 2010 Dec 29.

PMID:
21491455
[PubMed - indexed for MEDLINE]
10.

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

PMID:
18183034
[PubMed - indexed for MEDLINE]
11.

Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T.

Clin Pharmacol Ther. 2012 Apr;91(4):673-84. doi: 10.1038/clpt.2011.276. Epub 2012 Mar 7.

PMID:
22398970
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
[PubMed - indexed for MEDLINE]
13.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
14.

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR.

Curr Med Res Opin. 2008 Feb;24(2):591-9. doi: 10.1185/030079908X260871 .

PMID:
18205997
[PubMed - indexed for MEDLINE]
15.

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.

Kharasch ED, Walker A, Hoffer C, Sheffels P.

Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

PMID:
15536460
[PubMed - indexed for MEDLINE]
16.

Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.

Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA.

Pharmacotherapy. 2010 Aug;30(8):797-805. doi: 10.1592/phco.30.8.797.

PMID:
20653355
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Time-dependent interaction between lopinavir/ritonavir and fexofenadine.

van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW.

J Clin Pharmacol. 2006 Jul;46(7):758-67.

PMID:
16809801
[PubMed - indexed for MEDLINE]
18.

P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.

Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.

Int J Cancer. 2013 May 15;132(10):2439-47. doi: 10.1002/ijc.27912. Epub 2012 Nov 14.

PMID:
23090875
[PubMed - indexed for MEDLINE]
19.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.

Clin Pharmacol Ther. 2003 Sep;74(3):275-87. Erratum in: Clin Pharmacol Ther. 2004 Mar;75(3):249.

PMID:
12966371
[PubMed - indexed for MEDLINE]
20.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk